Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial

OBJECTIVE: Linagliptin, a dipeptidyl peptidase-4 inhibitor, recently demonstrated cardiovascular (CV) safety versus placebo in Asians with advanced type 2 diabetes mellitus (T2DM) in the CARMELINA(®) trial. We assessed its CV safety compared with the sulfonylurea glimepiride in Asians with relativel...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetol Int
Autori principali: Kadowaki, Takashi, Wang, Guang, Rosenstock, Julio, Yabe, Daisuke, Peng, Yongde, Kanasaki, Keizo, Mu, Yiming, Mattheus, Michaela, Keller, Annett, Okamura, Tomoo, Johansen, Odd Erik, Marx, Nikolaus
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Singapore 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7790983/
https://ncbi.nlm.nih.gov/pubmed/33479584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13340-020-00447-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi